Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson's and Alzheimer's Patients

Stock Information for Annovis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Annovis Bio Inc.

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
Annovis Bio Announces Participation in Forum Discussion at AD/PD(TM) 2024
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio
Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement
Annovis Bio to Participate in the 139th Yale CEO Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.